Evidence map›Paper›PMID 40094093›Full record

ArticleAvicenna journal of medical biotechnology

Isolation and Preliminary Characterization of a Novel scFv against

Samaneh Jahandar-Lashaki, Safar Farajnia, Effat Alizadeh, Farzin Seirafi, Asghar Tanoumand, Mohammad Kazem Hosseini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Samaneh Jahandar-LashakiDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Safar FarajniaDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Effat AlizadehDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Farzin SeirafiBiotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Asghar TanoumandDepartment of Microbiology, Maragheh University of Medical Sciences, Maragheh, Iran.
Mohammad Kazem HosseiniFaculty of Sciences, Molecular Biology and Genetic, Istanbul University, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Since the initial outbreak, the Methods: The RBD protein was produced, purified, and used as an antigen during biopanning. Six rounds of panning enriched RBD-specific phages and the binding affinity of binders were monitored by polyclonal phage ELISA. Subsequently, monoclonal phage ELISA was employed to identify specific binders. After sequence confirmation, the reactivity of the isolated anti-RBD scFv was evaluated. Additionally, bioinformatics tools determined the interaction between selected scFv and Results: The ELISA analysis demonstrated that the expressed RBD retains its structural integrity and effectively interacts with antibodies present in the sera of COVID-19 patients. Through screening a phage display library, a strong-binding scFv for RBD was discovered, which can effectively neutralize Conclusion: The findings of this study have led to the discovery of a novel scFv that effectively neutralizes

Indexed as

BioprospectingCOVID-19Phage display libraryReceptor binding domainSingle-chain antibodies

Identifiers

PMID40094093
PMCPMC11910022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.